End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,868 INR | +0.95% | +5.87% | +11.31% |
May. 10 | India's Dr. LalPath Labs posts higher Q4 profit rises on healthy testing demand | RE |
Apr. 11 | Metropolis Healthcare Books 10% Increase in Fiscal Q4 Overall Revenue | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 70.8 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.31% | 1.14B | B+ | ||
-15.71% | 8.57B | B+ | ||
+65.31% | 4.3B | C+ | ||
-9.46% | 2.47B | - | ||
-2.16% | 2.46B | B- | ||
-44.11% | 2.31B | B- | ||
-7.42% | 1.93B | C- | ||
-19.12% | 1.53B | A- | ||
-41.75% | 1.2B | C+ | ||
+16.15% | 986M | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- METROPOLIS Stock
- Ratings Metropolis Healthcare Limited